IFG Advisory’s Ionis Pharmaceuticals IONS Stock Holding History

IFG Advisory’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,678	Closed	-$212K	–	612
2025 Q4	$212K	Buy	+2,678	New	+$202K	0.01%	722
2019 Q3	–	Sell	-4,073	Closed	-$261K	–	421
2019 Q2	$261K	Buy	4,073 +58	+1%	+$4.1K	0.05%	295
2019 Q1	$325K	Sell	4,015 -374	-9%	-$24.1K	0.06%	256
2018 Q4	$237K	Buy	4,389 +21	+0.5%	+$1.07K	0.06%	274
2018 Q3	$225K	Buy	+4,368	New	+$205K	0.04%	344
2018 Q2	–	Sell	-4,920	Closed	-$216K	–	350
2018 Q1	$216K	Sell	4,920 -50	-1%	-$2.54K	0.05%	314
2017 Q4	$249K	Buy	+4,970	New	+$273K	0.06%	285

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IFG Advisory's IONS Position: Q1 2026 in Review

IFG Advisory sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 2,678 shares — an estimated $212K sold.

IFG Advisory first reported a position in IONS in Q4 2017 and held it in 7 quarters. The position peaked at $325K in Q1 2019. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

IFG Advisory reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
IFG Advisory sold 2,678 Ionis Pharmaceuticals shares in Q1 2026, an estimated $212K.
IFG Advisory first reported a position in Ionis Pharmaceuticals in Q4 2017 and held it in 7 quarters.
IFG Advisory's Ionis Pharmaceuticals position peaked at $325K in Q1 2019.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on IFG Advisory's 13F filing for Q1 2026, filed 12 May 2026.